{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T02:49:09Z","timestamp":1747190949024,"version":"3.40.5"},"reference-count":24,"publisher":"Wiley","license":[{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Taiwan Santen Pharmaceutical Co., Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Ophthalmology"],"published-print":{"date-parts":[[2022,10,29]]},"abstract":"<jats:p>Purpose. To investigate the efficacy and safety of switching to 0.0015% tafluprost ophthalmic solution with reduced benzalkonium chloride (BAK) on primary open-angle glaucoma (POAG) patients with corneal disorders under 0.005% latanoprost treatment. Material and Methods. This was a single-arm, open-label, switching study on adult POAG patients treated with latanoprost 0.005% for more than 3 months, with corneal disorders but no dry eye therapy. All patients were switched to tafluprost 0.0015% and followed up for 3 months. The primary outcome was the change in fluorescein staining score (National Eye Institute\/Industry [NEI] score) at the end of the study. Secondary outcomes included changes in intraocular pressure (IOP), tear break-up time (TBUT), hyperemia score, and other ocular and nonocular adverse events. Results. Of the 20 patients initially enrolled, 17 patients, all with POAG, completed the study. At the end of the study, the mean NEI score significantly decreased by 1.8\u2009\u00b1\u20092.2 (<jats:inline-formula>\n                     <a:math xmlns:a=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M1\">\n                        <a:mi>p<\/a:mi>\n                        <a:mo>&lt;<\/a:mo>\n                        <a:mn>0.01<\/a:mn>\n                     <\/a:math>\n                  <\/jats:inline-formula>). No significant changes in IOP were observed (12.8\u2009\u00b1\u20094.6\u2009mmHg at baseline vs. 12.3\u2009\u00b1\u20094.0\u2009mmHg on visit 2; <jats:inline-formula>\n                     <c:math xmlns:c=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M2\">\n                        <c:mi>p<\/c:mi>\n                        <c:mo>=<\/c:mo>\n                        <c:mn>0.470<\/c:mn>\n                     <\/c:math>\n                  <\/jats:inline-formula>). TBUT increased by 1.2\u2009\u00b1\u20091.7 seconds (<jats:inline-formula>\n                     <e:math xmlns:e=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M3\">\n                        <e:mi>p<\/e:mi>\n                        <e:mo>&lt;<\/e:mo>\n                        <e:mn>0.05<\/e:mn>\n                     <\/e:math>\n                  <\/jats:inline-formula>). The proportions of patients with no sign of hyperemia on the bulbar and palpebral conjunctiva increased from 58.5% to 64.7% at baseline (before switching to tafluprost treatment) to 94.1% and 94.1%, respectively, after switching to tafluprost treatment. Dry eye sensation scores were significantly reduced (<jats:inline-formula>\n                     <g:math xmlns:g=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M4\">\n                        <g:mi>p<\/g:mi>\n                        <g:mo>&lt;<\/g:mo>\n                        <g:mn>0.05<\/g:mn>\n                     <\/g:math>\n                  <\/jats:inline-formula>), while other ocular symptom scores did not change significantly. Conclusion. Switching to tafluprost 0.0015% significantly improved fluorescein staining score, TBUT, and conjunctival hyperemia while maintaining IOP control among POAG patients with corneal disorders.<\/jats:p>","DOI":"10.1155\/2022\/4885485","type":"journal-article","created":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T18:05:07Z","timestamp":1667066707000},"page":"1-7","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Efficacy and Safety of Tafluprost in Primary Open-Angle Glaucoma Patients with Corneal Disorders: A Taiwan Experience"],"prefix":"10.1155","volume":"2022","author":[{"given":"Ju-Kuo","family":"Lin","sequence":"first","affiliation":[{"name":"Chi Mei Medical Center, No. 901, Zhonghua Road, Yongkang, Tainan 71004, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fu-Tsung","family":"Wei","sequence":"additional","affiliation":[{"name":"Chi Mei Medical Center, No. 901, Zhonghua Road, Yongkang, Tainan 71004, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Chun","family":"Liu","sequence":"additional","affiliation":[{"name":"Chi Mei Medical Center, Liouying, No. 201, Taikang, Taikang Village, Liouying, Tainan 73657, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6931-4409","authenticated-orcid":true,"given":"Yung-Chang","family":"Yen","sequence":"additional","affiliation":[{"name":"Chi Mei Medical Center, Liouying, No. 201, Taikang, Taikang Village, Liouying, Tainan 73657, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1097\/ijg.0000000000000381"},{"issue":"6","key":"2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/bjophthalmol-2016-EGSguideline.003","article-title":"European glaucoma society terminology and guidelines for glaucoma, 4th edition\u2013chapter 3: treatment principles and options supported by the EGS foundation: Part 1: foreword; introduction; glossary; chapter 3 treatment principles and options","volume":"101","year":"2017","journal-title":"British Journal of Ophthalmology"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2012.02773.x"},{"issue":"4","key":"4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0002-9394(98)00223-2","article-title":"Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group","volume":"126","author":"Collaborative Normal-Tension Glaucoma Study Group","year":"1998","journal-title":"American Journal of Ophthalmology"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.10.1268"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1097\/ijg.0b013e31829ea2e6"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1177\/112067210701700311"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.86.4.418"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.79.4.339"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1097\/opx.0000000000000667"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2003.12.007"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1007\/bf00184009"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2013.0132"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1097\/ijg.0000000000000265"},{"issue":"4","key":"15","first-page":"221","article-title":"Report of the National Eye Institute\/Industry workshop on clinical trials in dry eyes","volume":"21","author":"M. A. Lemp","year":"1995","journal-title":"CLAO Journal: Official Publication of the Contact Lens Association of Ophthalmologists, Inc"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2010.03.001"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2012-303026"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.13329"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1097\/ijg.0000000000000020"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.ijo_165_21"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.2147\/opth.s209942"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1240537"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12131"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0549-0"}],"container-title":["Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/joph\/2022\/4885485.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/joph\/2022\/4885485.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/joph\/2022\/4885485.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T18:05:16Z","timestamp":1667066716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/joph\/2022\/4885485\/"}},"subtitle":[],"editor":[{"given":"Su-Ho","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,10,29]]},"references-count":24,"alternative-id":["4885485","4885485"],"URL":"https:\/\/doi.org\/10.1155\/2022\/4885485","relation":{},"ISSN":["2090-0058","2090-004X"],"issn-type":[{"type":"electronic","value":"2090-0058"},{"type":"print","value":"2090-004X"}],"subject":[],"published":{"date-parts":[[2022,10,29]]}}}